CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $49,763 | -22.8% | 1,096,354 | -4.5% | 0.08% | -18.3% |
Q2 2023 | $64,445 | +23.2% | 1,147,929 | -0.8% | 0.10% | +14.3% |
Q1 2023 | $52,323 | +8.3% | 1,156,810 | -2.7% | 0.09% | -6.2% |
Q4 2022 | $48,305 | -99.9% | 1,188,321 | -4.6% | 0.10% | -41.2% |
Q3 2022 | $81,374,000 | -4.1% | 1,245,199 | -10.8% | 0.16% | +5.1% |
Q2 2022 | $84,850,000 | +4.7% | 1,396,258 | +8.2% | 0.16% | +45.4% |
Q1 2022 | $81,030,000 | -18.8% | 1,290,905 | -1.9% | 0.11% | -10.7% |
Q4 2021 | $99,736,000 | -3.8% | 1,316,123 | +42.1% | 0.12% | -4.7% |
Q3 2021 | $103,638,000 | -29.5% | 925,914 | +1.9% | 0.13% | -28.7% |
Q2 2021 | $147,101,000 | – | 908,652 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |